Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2

Responding quickly to emerging respiratory viruses, such as SARS-CoV-2 the causative agent of coronavirus disease 2019 (COVID-19) pandemic, is essential to stop uncontrolled spread of these pathogens and mitigate their socio-economic impact globally. This can be achieved through drug repurposing, wh...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Pharmacology & therapeutics (Oxford) 2022-05, Vol.233, p.108027-108027, Article 108027
Hauptverfasser:	Niemeyer, Brian F., Benam, Kambez H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-inflammatory Anticoagulant Anticoagulants - pharmacology Anticoagulants - therapeutic use Antiviral Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Coronavirus COVID-19 Drug Treatment Drug repurposing Host-targeting therapies Humans Nafamostat mesylate Pandemics SARS-CoV-2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!